Becton Dickinson & Co. (BDX) PE Ratio stood at $52.46: Odds are Looking Good After Recent Activity

Becton Dickinson & Co. (NYSE: BDX) open the trading on Thursday, with great promise as it jumped 2.00% to $238.40, before settling in for the price of $233.73 at the close. Taking a more long-term approach, BDX posted a 52-week range of $224.00-$287.32.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 4.18%. Meanwhile, its Annual Earning per share during the time was 52.43%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 6.89%. This publicly-traded company’s shares outstanding now amounts to $290.39 million, simultaneously with a float of $288.61 million. The organization now has a market capitalization sitting at $68.90 billion. At the time of writing, stock’s 50-day Moving Average stood at $234.65, while the 200-day Moving Average is $243.01.

Becton Dickinson & Co. (BDX) Ownership Facts and Figures

Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Medical Instruments & Supplies industry. Becton Dickinson & Co.’s current insider ownership accounts for 0.14%, in contrast to 87.69% institutional ownership. According to the most recent insider trade that took place on Jun 10 ’24, this organization’s SVP,Controller&Chief Acct Off sold 300 shares at the rate of 239.31, making the entire transaction reach 71,793 in total value, affecting insider ownership by 1,976. Preceding that transaction, on May 15 ’24, Company’s EVP and President EMEA sold 3,300 for 236.73, making the whole transaction’s value amount to 781,224. This particular insider is now the holder of 11,308 in total.

Becton Dickinson & Co. (BDX) Earnings and Revenue Records

Becton Dickinson & Co.’s EPS increase for this current 12-month fiscal period is 6.89% and is forecasted to reach 14.27 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 8.60% through the next 5 years, which can be compared against the 52.43% growth it accomplished over the previous five years trading on the market.

Becton Dickinson & Co. (NYSE: BDX) Trading Performance Indicators

Let’s observe the current performance indicators for Becton Dickinson & Co. (BDX). It’s Quick Ratio in the last reported quarter now stands at 0.97. The Stock has managed to achieve an average true range (ATR) of 4.18. Alongside those numbers, its PE Ratio stands at $52.46, and its Beta score is 0.43. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 3.49. Similarly, its price to free cash flow for trailing twelve months is now 22.77.

In the same vein, BDX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 4.54, a figure that is expected to reach 3.31 in the next quarter, and analysts are predicting that it will be 14.27 at the market close of one year from today.

Technical Analysis of Becton Dickinson & Co. (BDX)

[Becton Dickinson & Co., BDX] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 42.88% While, its Average True Range was 4.26.

Raw Stochastic average of Becton Dickinson & Co. (BDX) in the period of the previous 100 days is set at 58.97%, which indicates a major fall in contrast to 71.48% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 21.13% that was higher than 18.11% volatility it exhibited in the past 100-days period.